From Health Consumers To Health Citizens | Jane Sarasohn-Kahn, THINK Health & Health Populi Blog

from The Health Care Blog at http://bit.ly/35FAI0v on November 26, 2019 at 05:15PM By JESSICA DAMASSA, WTF HEALTH Jane Sarasohn-Kahn, health economist, advisor and author of “HealthConsuming: From Health Consumer to Health Citizen” explains how consumers are getting screwed by the American health system because of the industry’s lack of transparency and lack of privacy […]

ICER Releases Report on JAK Inhibitors in Treatment of RA

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2DjsrTS on November 26, 2019 at 03:34PM The Institute for Clinical and Economic Review (ICER) in a new report suggests a roughly 25 percent discount on AbbVie’s upadacitinib, which costs $59,860 per year. ICER reviewed the following drugs used to treat rheumatoid arthritis: AbbVie’s upadacitinib (Rinvoq); Pfizer’s tofacitinib […]

Understanding U.S. Health Systems

from RAND Research Topic: Health and Health Care at http://bit.ly/35FEg2v on November 26, 2019 at 02:10PM Introduction As hospitals and physician organizations increasingly vertically integrate, there is an important opportunity to use health systems to improve performance. Prior research has largely relied on secondary data sources, but little is known about how health systems are […]

Framing Flexible Spending Accounts: A Large‐Scale Field Experiment on Communicating the Return on Medical Savings Accounts

from Health Economics at http://bit.ly/2siSN66 on November 26, 2019 at 09:51AM Abstract Tax‐preferred health savings devices such as Flexible Spending Accounts (FSAs) and Health Savings Accounts (HSAs) offer employees potentially valuable financial instruments for directing pre‐tax earnings to eligible medical expenses. Despite their increasing popularity as an employee benefit, however, there is little causal evidence […]

Persistent Effects of Temporary Incentives: Evidence from a Nationwide Health Insurance Experiment

from Health Economics at http://bit.ly/2DszXff on November 26, 2019 at 01:43AM Temporary incentives are offered in anticipation of persistent effects, but these are seldom estimated. We use a nationwide randomized experiment in the Philippines to estimate effects three years after the withdrawal of two incentives for health insurance. A premium subsidy had a persistent effect […]

How Do Couples Choose Individual Insurance Plans? Evidence from Medicare Part D

from Health Economics at http://bit.ly/2QNzL1T on November 26, 2019 at 01:43AM This research is the first economic study to investigate how couples make enrollment choices in individual insurance markets. I leverage administrative records for Medicare Part D enrollees to distinguish widows and divorcees from married couples. I estimate a stochastic choice model of household demand […]

Causes of haze and its health effects in Singapore; a replication study

from Health Economics at http://bit.ly/2DhpqTU on November 26, 2019 at 01:43AM Intermittently Singapore suffers from severe air pollution in periods of intense forest and peatland fires on neighboring South-Asian islands. A recent American Economic Review article modeled the causal relationships between fire intensity in Indonesia and air pollution (PSI) in Singapore, and between PSI and […]

Whistleblowers, The False Claims Act, and the Behavior of Healthcare Providers

from Health Economics at http://bit.ly/2OHXFt6 on November 26, 2019 at 01:43AM This paper studies the effects of litigation by whistleblowers against healthcare providers for misreporting claims for payment to the Medicare program. Under the U.S. False Claims Act, whistleblowers bring lawsuits on behalf of the government in exchange for a share of recovered payments. I […]

Intergenerational Health Mobility: Magnitudes and Importance of Schools and Place

from Health Economics at http://bit.ly/33pBsFz on November 26, 2019 at 01:43AM Nascent research suggests intergenerational health mobility may be relatively high and non-genetic factors may make room for policy intervention. This project broadens this direction by considering heterogeneous intergenerational health mobility in spatial and contextual patterns. With 14,797 parent-child pairs from a school-based representative panel […]

Investments in Worker Health and Labor Productivity: Evidence from Vietnam

from Health Economics at http://bit.ly/35xKiCl on November 26, 2019 at 01:43AM The health and safety of workers are important determinants of their productivity. In manufacturing industries, occupational health and safety (OHS) measures are critical workplace practices for employers to ensure better working conditions for employees, particularly in industries with rampant indoor pollution. This paper studies […]

ICER Accepting Nominations for New Members of Voting Panels

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/34kVzWy on November 25, 2019 at 08:17PM The Institute for Clinical and Economic Review (ICER) announced it is accepting nominations as it seeks new members for its independent review panels. ICER has three panels: The California Technology Assessment Forum (CTAF) The Midwest Comparative Effectiveness Public Advisory Council (Midwest […]

Transparency and hospital prices

from Healthcare Economist at http://bit.ly/2Oh2RoH on November 25, 2019 at 06:29PM Health care costs are high in the U.S., making up 17.9% of the U.S. economy. The Economist reports on recent key drivers of US health care cost…and the answer isn’t drugs. Mr Trump has correctly identified a big villain behind health-care cost inflation, and […]

HEDS at the Vascular Societies Annual Scientific Meeting

from Health Economics and Decision Science Blog @ ScHARR at http://bit.ly/2KSHt75 on November 25, 2019 at 12:35PM Professor Jonathan Michaels HEDS colleagues will be in attendance at The Vascular Societies’ Annual Scientific Meeting later this week. The meeting takes place from 27th-29th November at Manchester Central Convention Complex. https://www.vascularsociety.org.uk/asm/vsasm_2019.aspx  We will be showcasing the Vascular […]

The effect of college education on health and mortality: Evidence from Canada

from Health Economics at http://bit.ly/33nKNh6 on November 25, 2019 at 09:54AM Abstract We investigate the returns to college attendance in Canada in terms of health and mortality reduction. To do so, we first use a dynamic health microsimulation model to document how interventions that incentivize college attendance among high school graduates may impact their health […]

The Evolution of Mental Health in the Context of Transitory Economic Changes

from Applied Health Economics and Health Policy at http://bit.ly/2XJk3pT on November 25, 2019 at 04:33AM Abstract Background Mental health disorders are highly prevalent across countries. They increase over time and impose a severe burden on individuals and societies. Objective This paper examines the evolution of mental health over a period of 15 years, paying special attention […]

How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness

from PharmacoEconomics at http://bit.ly/2DdoIXN on November 25, 2019 at 02:09AM Abstract Background and Objective The extrapolation of estimated hazard functions can be an important part of cost-effectiveness analyses. Given limited follow-up time in the sample data, it may be expected that the uncertainty in estimates of hazards increases the further into the future they are […]

Transferability of Economic Evaluations of Treatments for Advanced Melanoma

from PharmacoEconomics at http://bit.ly/34hd2iJ on November 25, 2019 at 02:09AM Abstract Background Differing methodological requirements and decision-making criteria are recognised as barriers to transferability of cost-effectiveness analysis (CEA) across jurisdictions. Objective We assessed the generic and specific transferability of published CEAs of systemic treatments for advanced melanoma to the Irish setting. Methods CEAs of treatments […]

Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review

from PharmacoEconomics at http://bit.ly/2Ofjz7W on November 25, 2019 at 02:09AM Abstract Objectives Our aim was to systematically review published evidence on the construct validity, test-retest reliability and responsiveness of generic preference-based measures (PBMs) used in East and South-East Asia. Methods This systematic review was guided by the COSMIN guideline. A literature search on the MEDLINE, […]

Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan

from PharmacoEconomics at http://bit.ly/33fOaX6 on November 25, 2019 at 02:09AM Abstract Aim The recently developed direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infections are costly. Cost-effectiveness analyses of DAAs require accurate healthcare expenditure estimates for the various HCV disease states, but few studies have produced such estimates using national-level data. This study utilized nationally […]

Never enough

from Healthcare Economist at http://bit.ly/2OJOSqk on November 24, 2019 at 09:46PM I recently finish a very interesting book on drugs and addiction titled Never Enough: The Neuroscience and Experience of Addiction. The book was written by Judith Grisel, who is a not only a professor and neuroscientist, but also a former drug addict. The book […]

Developing a Real-World Study Protocol

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2QTeF1U on November 24, 2019 at 08:07PM Study protocols developed for real-world studies introduce added complexity and must be “developed in such a way as not to alter real-world routine clinical care patterns,” a recent white paper by Evidera states. “The protocol, derived from the sponsor’s strategic needs, […]

Article Spotlights Orphan Drugs

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2D99za1 on November 24, 2019 at 08:07PM A recent article published in the European Journal of Health Economics spotlights the organ drug industry, including some implications of such high-cost drugs. Despite the high cost of the drugs, the article states, society remains willing to continue funding for rare […]

The Role of Cost-Effectiveness Assessments in Decision Making

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2s6dTEu on November 24, 2019 at 07:37PM A recent article by Xcenda looks at how cost-effectiveness assessments are used in reimbursement and pricing decisions in a number of major markets. The article highlight’s Novartis’ spinal muscular atrophy drug, Zolgensma, which carries a hefty $2.1 million price tag. “Many […]